Online inquiry

IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9185MR)

This product GTTS-WQ9185MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FOLR1 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000802.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2348
UniProt ID P15328
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9185MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11712MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MILR1444A
GTTS-WQ1728MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ2077MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ117MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 11F8
GTTS-WQ7721MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ3073MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ1297MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ5412MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD74-DOX (ADC)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW